Wei-Yu Chi s a medical doctor and current Ph.D. candidate at Weill Cornell Medicine, specializing in the development of single-cell sequencing technologies. With a focus on oncology, he is pioneering a novel sequencing method to profile transcription factor binding in single cells—a critical advance for understanding blood cancers such as leukemia and lymphoma and identifying potential drug targets.

Prior to his Ph.D., he was an intern physician at the National Taiwan University Hospital and a research fellow at Johns Hopkins University, where he contributed to advancements in single-cell imaging to study cancer signaling pathways.

 

Beyond the lab, he has actively explored the intersection of science and business. He participated in a startup competition and worked as a business development trainee at the Cornell Center for Technology Licensing, where he practiced skills in evaluating patentability, assessing commercial potential, and creating marketing strategies for new biomedical inventions. 

 

His scientific expertise and business acumen position him to impact the future of biotech investment, aiming to bridge the gap between innovative biomedical research and market-ready solutions. As a Research Associate at Atoll Financial Group, Wei-Yu works with the Biotech and Life Sciences team identifying promising technologies and providing scientific and strategic guidance to the banking team when developing investment theses for clients.